Beyond Mutations: miR-101a as a Molecular Bridge Linking Ethanolamine, Microbial Dysbiosis, and Inflammation in Obesity-Driven Colorectal Cancer

Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, with obesity recognized as a major modifiable risk factor. Obesity-associated CRC is characterized by systemic low-grade inflammation, altered lipid metabolism, and gut microbial dysbiosis, all of which converge to create a tumor-permissive environment. Emerging evidence implicates miR-101a, the murine homolog of human miR-101, as a key molecular mediator linking metabolic dysfunction, microbial metabolites, and epithelial homeostasis. Traditionally regarded as a tumor suppressor by repressing oncogenes such as EZH2, MCL-1, and COX-2, miR-101a appears to exhibit a paradoxical tumor-promoting role in obese colon. Elevated dietary and microbially derived ethanolamine induces miR-101a overexpression in colonic epithelial cells. This aberrant induction impairs goblet cell differentiation and reduces MUC2 mucin biosynthesis, disrupting the mucus barrier and leading to a “leaky gut” phenotype. Barrier dysfunction permits microbial translocation and endotoxemia, which activate NF-κB-driven inflammatory cascades and amplify COX-2 signaling. The resulting chronic inflammation promotes epithelial proliferation, generates mutagenic reactive oxygen species, and activates pro-survival pathways such as STAT3 and AKT, collectively driving adenoma initiation and progression. Importantly, this ethanolamine-miR-101a axis represents a novel mechanistic link between diet, the microbiota, and cancer biology. Translationally, miR-101a holds promise as a biomarker of early barrier dysfunction and CRC risk, detectable in tissue, serum, or fecal samples. Furthermore, microbiome-targeted interventions, dietary modifications, or direct inhibition of miR-101a may offer innovative therapeutic strategies. Understanding the context-dependent duality of miR-101a underscores the complexity of miRNA biology and highlights its potential as a target for preventing obesity-driven CRC.